Helixgate https://validator.w3.org/feed/docs/rss2.html STAT+: Health system CEOs get off easy at Congressional hearing on affordability  STAT+: AIDS group sues Trump administration over undisclosed agreement with Gilead STAT+: FDA launches effort to speed up clinical trials, using AI Method Identifies Cellular Makeup of Microenvironments Favoring Tumor Metastasis Opinion: Healthcare or health care? Help STAT decide FDA debuts plan to collect real-time clinical trial data The crown for healthcare admin tech is still up for grabs Opinion: FDA commissioner: ‘Smarter,’ real-time clinical trials could transform drug development Hikma vs. Amarin generic drug case heads to Supreme Court arguments Fauci adviser David Morens indicted for concealing emails, avoiding records requests ‘Type’ Casting: Flagship-Founded Serif Modifying DNA into New Therapy Class Pfizer deals extend patent life for a top-selling rare disease drug Boehringer dual-acting obesity shot hits mark in Phase 3 trial Prostate Cancer Therapy Targets Disordered Region of Androgen Receptor Rocket’s PRV goes for $180M; Oruka targets $500M offering AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3 FDA flags concerns for AstraZeneca’s camizestrant, Truqap ahead of advisory committee meeting FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed US tariffs: How will the latest changes impact drug discovery?  Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’ AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel FDA claims trial ‘manipulation’ tainted approval of ChemoCentryx drug FDA alleges ‘manipulated’ data supported approval of Amgen’s autoimmune drug Coultreon banks $125M to support testing of former Galapagos immune drug Adaptyv Bio reveals latest results in protein design competition Predicting consequences of new hepatitis B vaccine recs Novartis’ sales dip as generics pressure intensifies, radioequivalents loom Lilly strikes second partnership this year for recombinase-based gene editing Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead. Big Pharma–backed Coultreon bags $125M series A to unlock alternative immune pathway Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up Opinion: Why do discussions about ‘brain health’ ignore mental illness? Garijo starts as Sanofi CEO with window to ease reliance on Dupixent Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts, but no deals in the works Heritable immunization of mice against Lyme disease enables ecological disease prevention Shedding light on the undiscovered pathways of yeast metabolism Historic FDA approval brings first gene therapy for genetic deafness Home Retron-Powered Approach Enables Genome Editing Across Diverse Bacterial Species New U.S. recommendation on hepatitis B vaccine will have dire consequences, studies project STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy Erasca reports RAS cancer drug data after legal threat from Revolution Sun Pharma Aims for Top 3 in Women’s Health with $11.75B Organon Purchase Dems say RFK Jr. has a pattern of failing to answer their questions Revolution Medicines threatens to sue Erasca over patent, efficacy claims Trump administration warns against using federal dollars on fentanyl test strips Utah doctors demand suspension of Doctronic AI program Anticancer Strategy Targets Defense Mechanism in Senescent Cells